||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Kontakt
Impressum
Bankleitzahlen - online.de


Helsinn announces its support for the International Fellowship Program (IFP), a joint project founded by the Society for Translational Oncology (STO) and Chinese Society of Clinical Oncology (CSCO)

Helsinn Healthcare SA /
Helsinn announces its support for the International Fellowship Program (IFP), a
joint project founded by the Society for Translational Oncology (STO) and
Chinese Society of Clinical Oncology (CSCO)
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.



 Helsinn announces its support for the International Fellowship Program (IFP), a
joint project founded by the Society for Translational Oncology (STO) and
Chinese Society of Clinical Oncology (CSCO)



Lugano, Switzerland, October 10, 2017 - Helsinn, a Swiss pharmaceutical group
focused on building quality cancer care products, today announces its support
for the International Fellowship Program (IFP), which is a joint project founded
by the US-based professional association Society for Translational Oncology
(STO) and Chinese Society of Clinical Oncology (CSCO).

The mission of the program is to address the needs of young Chinese oncologists,
the next generation of experts, and aims to enhance the clinical skills, as well
as expertise in the design and conduction of clinical trials in oncology during
this promising and rapidly evolving era of precision medicines and immuno-
oncology. The IFP program is sponsored by Helsinn, OrigiMed and Sanofi.

The winners this year, announced at the recent 20th annual meeting of the STO-
CSCO Joint Symposium, were Dr. WEI Jia from Drum Tower Hospital Affiliated to
Medical School of Nanjing University, and Dr. YANG Sheng from Cancer Hospital of
Chinese Academy of Medical Sciences (CAMS). They will visit the United States
for three months and participate in a series of curriculum as well as
communication focused on clinical trials, translational medicine and novel drug
development led by Harvard Medical School and Alliance for Clinical Trials in
Oncology. They will also have the opportunity to visit the US Food and Drug
Administration (FDA) to learn and discuss topics of common academic interests.

Hans Schmid, Chairman of the Board of Directors, Helsinn Pharmaceuticals
(Beijing) Co. Ltd., added:

 "I am delighted to announce today Helsinn's support for the International
Fellowship Program, which helps develop young oncologists. I would like to
congratulate this year's winners and participants as these young Chinese
oncologists are the next generation clinical investigators with outstanding
ability and the potential to be the future leaders. They share our values and
our commitment to improving the lives of patients living with cancer."







About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of
marketed cancer care products and a robust drug development pipeline. Since
1976, Helsinn has been improving the everyday lives of patients, guided by core
family values of respect, integrity and quality. The Group works across
pharmaceuticals, biotechnology, medical devices and nutritional supplements and
has expertise in research, development, manufacture and the commercialization of
therapeutic and supportive care products for cancer, pain and inflammation and
gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to
support early-stage investment opportunities in areas of unmet patient need. The
company is headquartered in Lugano, Switzerland, with operating subsidiaries in
Switzerland, Ireland, and the U.S., as well as a product presence in
approximately 190 countries globally.



About Society for Translation Oncology (STO)

STO is a non-profit, professional association committed to speeding the
discovery and translation of important new treatments in the field of cancer
medicine to the practice of global oncology by bringing knowledge and strategies
for critical new developments in cancer treatment to the community oncologist,
bridging the "translational gap" between discovery and delivery of care to  the
patient, and providing educational activities to improve physician competencies
for screening, prevention, diagnosis, treatment, and supportive care of cancer
patients.

http://www.sto-online.org/



About Chinese Society of Clinical Oncology (CSCO)

The Chinese Society of Clinical Oncology (CSCO) is a public academic and
professional organization comprised of clinical oncology professionals, relevant
entities, and public institutions.

CSCO is committed to developing continuing medical and clinical oncology
education, enhancing multi-disciplinary collaboration, encouraging multi-center
research, promoting the standardization of tumor diagnosis and treatment, and
furthering the development of clinical oncology as a benefit all patients.

http://www.csco.ac.cn/







For more information:

Helsinn Group Media Contact

Paola Bonvicini

Group Head of Communication

Lugano, Switzerland

Tel: +41 (0) 91 985 21 21

Info-hhc@helsinn.com

* Please visit www.helsinn.com
* We are on Twitter. Follow us @HelsinnGroup





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Helsinn Healthcare SA via GlobeNewswire



 
 ||| Themen-Infos 
· Mehr zu dem Thema Allgemeine Nachrichten

Der meistgelesene Artikel zu dem Thema Allgemeine Nachrichten:
FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.060 Sekunden